Cargando…

Improving Osteosarcoma Treatment: Comparative Oncology in Action

Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarone, Lidia, Mareschi, Katia, Tirtei, Elisa, Giacobino, Davide, Camerino, Mariateresa, Buracco, Paolo, Morello, Emanuela, Cavallo, Federica, Riccardo, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783386/
https://www.ncbi.nlm.nih.gov/pubmed/36556464
http://dx.doi.org/10.3390/life12122099
_version_ 1784857566503763968
author Tarone, Lidia
Mareschi, Katia
Tirtei, Elisa
Giacobino, Davide
Camerino, Mariateresa
Buracco, Paolo
Morello, Emanuela
Cavallo, Federica
Riccardo, Federica
author_facet Tarone, Lidia
Mareschi, Katia
Tirtei, Elisa
Giacobino, Davide
Camerino, Mariateresa
Buracco, Paolo
Morello, Emanuela
Cavallo, Federica
Riccardo, Federica
author_sort Tarone, Lidia
collection PubMed
description Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for these OSA patients in recent decades. As OSA is a rare and “orphan” tumor, with no distinct targetable driver antigens, the development of new efficient therapies is still an unmet and challenging clinical need. Appropriate animal models are therefore critical for advancement in the field. Despite the undoubted relevance of pre-clinical mouse models in cancer research, they present some intrinsic limitations that may be responsible for the low translational success of novel therapies from the pre-clinical setting to the clinic. From this context emerges the concept of comparative oncology, which has spurred the study of pet dogs as a uniquely valuable model of spontaneous OSA that develops in an immune-competent system with high biological and clinical similarities to corresponding human tumors, including in its metastatic behavior and resistance to conventional therapies. For these reasons, the translational power of studies conducted on OSA-bearing dogs has seen increasing recognition. The most recent and relevant veterinary investigations of novel combinatorial approaches, with a focus on immune-based strategies, that can most likely benefit both canine and human OSA patients have been summarized in this commentary.
format Online
Article
Text
id pubmed-9783386
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97833862022-12-24 Improving Osteosarcoma Treatment: Comparative Oncology in Action Tarone, Lidia Mareschi, Katia Tirtei, Elisa Giacobino, Davide Camerino, Mariateresa Buracco, Paolo Morello, Emanuela Cavallo, Federica Riccardo, Federica Life (Basel) Commentary Osteosarcoma (OSA) is the most common pediatric malignant bone tumor. Although surgery together with neoadjuvant/adjuvant chemotherapy has improved survival for localized OSA, most patients develop recurrent/metastatic disease with a dismally poor outcome. Therapeutic options have not improved for these OSA patients in recent decades. As OSA is a rare and “orphan” tumor, with no distinct targetable driver antigens, the development of new efficient therapies is still an unmet and challenging clinical need. Appropriate animal models are therefore critical for advancement in the field. Despite the undoubted relevance of pre-clinical mouse models in cancer research, they present some intrinsic limitations that may be responsible for the low translational success of novel therapies from the pre-clinical setting to the clinic. From this context emerges the concept of comparative oncology, which has spurred the study of pet dogs as a uniquely valuable model of spontaneous OSA that develops in an immune-competent system with high biological and clinical similarities to corresponding human tumors, including in its metastatic behavior and resistance to conventional therapies. For these reasons, the translational power of studies conducted on OSA-bearing dogs has seen increasing recognition. The most recent and relevant veterinary investigations of novel combinatorial approaches, with a focus on immune-based strategies, that can most likely benefit both canine and human OSA patients have been summarized in this commentary. MDPI 2022-12-14 /pmc/articles/PMC9783386/ /pubmed/36556464 http://dx.doi.org/10.3390/life12122099 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Tarone, Lidia
Mareschi, Katia
Tirtei, Elisa
Giacobino, Davide
Camerino, Mariateresa
Buracco, Paolo
Morello, Emanuela
Cavallo, Federica
Riccardo, Federica
Improving Osteosarcoma Treatment: Comparative Oncology in Action
title Improving Osteosarcoma Treatment: Comparative Oncology in Action
title_full Improving Osteosarcoma Treatment: Comparative Oncology in Action
title_fullStr Improving Osteosarcoma Treatment: Comparative Oncology in Action
title_full_unstemmed Improving Osteosarcoma Treatment: Comparative Oncology in Action
title_short Improving Osteosarcoma Treatment: Comparative Oncology in Action
title_sort improving osteosarcoma treatment: comparative oncology in action
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783386/
https://www.ncbi.nlm.nih.gov/pubmed/36556464
http://dx.doi.org/10.3390/life12122099
work_keys_str_mv AT taronelidia improvingosteosarcomatreatmentcomparativeoncologyinaction
AT mareschikatia improvingosteosarcomatreatmentcomparativeoncologyinaction
AT tirteielisa improvingosteosarcomatreatmentcomparativeoncologyinaction
AT giacobinodavide improvingosteosarcomatreatmentcomparativeoncologyinaction
AT camerinomariateresa improvingosteosarcomatreatmentcomparativeoncologyinaction
AT buraccopaolo improvingosteosarcomatreatmentcomparativeoncologyinaction
AT morelloemanuela improvingosteosarcomatreatmentcomparativeoncologyinaction
AT cavallofederica improvingosteosarcomatreatmentcomparativeoncologyinaction
AT riccardofederica improvingosteosarcomatreatmentcomparativeoncologyinaction